secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001193125-21-325243
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Q3 net loss $87.2M; FYARRO PDUFA Nov 26; cash $161.4M
----------------------------------------------------------

- FYARRO (nab-sirolimus) NDA under FDA priority review with PDUFA target Nov 26, 2021.
- Ended Q3 with $161.4M cash; expected runway into 2024 post merger & $155M PIPE.
- Net loss $87.2M for Q3, primarily from $74.2M non-cash impairment related to merger.
- Appointed Brendan Delaney COO, Loretta Itri CMO (Q4), Scott Giacobello CFO (Nov 28).
- Plan to initiate registrational trial in TSC1/TSC2 tumors by end 2021 or early 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521325243/0001193125-21-325243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312521325243/d249085d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-325243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer